FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.

March 21, 2025

Vol.51 No.11

Drugs & Targets

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

March 21, 2025

Vol.51 No.11

Drugs & Targets

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

FDA granted Orphan Drug designation to rhenium obisbemeda (186Re) for the treatment of leptomeningeal metastases in patients with lung cancer.

March 14, 2025

Vol.51 No.10

Clinical Roundup

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

B-cell acute lymphoblastic leukemia is a common type of ALL in adults.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.

March 07, 2025

Vol.51 No.09

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

YOU MAY BE INTERESTED IN

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

Renew today!

Subscriber content

Never miss an issue!

Login

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

YOU MAY BE INTERESTED IN

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA grants Orphan Drug designation to rhenium obisbemeda for leptomeningeal metastases in lung cancer

CAR T-cell therapy for B-ALL results in high incidence of durable response in phase I/II study

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

Never miss an issue!

Login

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)